NADAC acquisition cost data for ACETYLCYSTEINE 10% VIAL (NOT FOR INJECTION). This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00409330703 | $0.3811 | 2022-04-20 | Rx |
| 63323069130 | $0.3811 | 2022-04-20 | Rx |
| 00409330703 | $0.3811 | 2022-04-20 | Rx |
| 63323069130 | $0.3811 | 2022-04-20 | Rx |
| 00409330703 | $0.3811 | 2022-04-20 | Rx |
| 63323069130 | $0.3811 | 2022-04-20 | Rx |
| 00409330703 | $0.3811 | 2022-04-20 | Rx |
| 63323069130 | $0.3811 | 2022-04-20 | Rx |
| 00409330703 | $0.3811 | 2022-04-20 | Rx |
| 63323069130 | $0.3811 | 2022-04-20 | Rx |
Generic: Acetylcysteine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.0M | 28,050 | 7,361 | $0.8301 |
| 2020 | $1.7M | 20,886 | 5,149 | $0.8782 |
| 2021 | $1.6M | 16,659 | 4,039 | $0.9432 |
| 2022 | $1.8M | 17,333 | 4,323 | $1.06 |
| 2023 | $1.8M | 18,326 | 4,830 | $1.02 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.